CAPHRA calls for regulated access to e-cigarettes in Australia

Dec.16.2022
CAPHRA calls for regulated access to e-cigarettes in Australia
CAPHRA submits consultation document to TGA for access to legal electronic cigarettes and nicotine in Australia.

According to a submission by the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA), just over 1% of people capable of writing nicotine scripts actually do so. Less than one-third of authorized prescribers are publicly available for adult smokers seeking to switch to nicotine e-cigarettes due to Australia's failed medicalized model.


CAPHRA has submitted a consultation paper to the Therapeutic Goods Administration (TGA) in Australia, discussing various options for legally obtaining electronic cigarettes and nicotine.


Australia remains the only Western democracy that requires a prescription for nicotine electronic cigarettes. The public consultation period regarding the proposed reform on the regulation of nicotine e-cigarette products in Australia began on November 30th and ended on January 16th, 2023.


Over the past decade, smoking rates in Australia have remained stable, particularly among vulnerable and disadvantaged communities. Nancy Loucas, the executive coordinator of CAPHRA, stated that "electronic cigarettes are one of the most effective methods for smokers worldwide to quit smoking, and access to them at retail outlets should have been restricted long ago.


CAPHRA stated that several countries, including the European Union, the United Kingdom, New Zealand, and Canada, are currently utilizing electronic cigarettes and reduced harm products to influence the rapid decline in smoking prevalence in these countries.


Ms. Lucas stated that the most deadly product to the public, combustible tobacco, is still readily available at any ordinary retailer, which is a mockery of public health.


Australia needs to determine whether their nicotine policy decisions are based on science, evidence, and facts to promote and maintain the health of their population, or if they choose money over health regarding tobacco consumption taxes and other possible funding they may receive due to their severe policy, which has proven to be a failure, according to CAPHRA.


Australian politicians and officials may not like to hear it, but if they want to see success, they need only cross the Tasman Sea. New Zealand has adopted an active harm reduction approach towards tobacco, and in the past decade, with the implementation of the Smokefree 2025 goal, their overall smoking rate has halved. Now they aim to achieve a regular smoking rate of only 5% or less. "Ms Loucas said.


Similarly, CAPHRA wrote that if youth access is truly a concern for Australian policymakers, the only solution is proper regulation and imposing strict fines and license revocations for non-compliant retailers. New Zealand's 2020 e-cigarette legislation and subsequent regulations achieved this.


According to Ms. Loucas, New Zealand has an effective consumer framework. In fact, in the past year alone, over 150,000 New Zealanders have switched from deadly combustible products to safer nicotine alternatives.


The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) believes that a regulated consumer market will enable Australia to have necessary control over the quality and quantity of products sold by community retailers. It also allows for products to be restricted to adults only – similar to alcohol and combustible cigarettes.


The report points out that there is currently a prevalence of unregulated black market products in Australia, with no regulatory control over their content or access for individuals under the age of 18.


We, on behalf of our nine member organizations, have submitted a letter of objection to the consultation document advocating for the 'gateway theory.' Despite the document's claim of evidence that electronic cigarettes lead to youth smoking, the gateway theory has been both confirmed and questioned by numerous international research institutions. Ms. Loucas stated that electronic cigarettes are an exit from smoking, not an entrance.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules
The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.
Sep.03
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia Adds Vapes to “Strategic Goods” List, Illegal Cross-Border Trade Faces Up to Five Years in Prison
Russia will place e-cigarettes and related nicotine products under its “strategic goods” framework from August 20, 2026. According to TVP World’s report published on August 19, the newly listed items include e-cigarettes, electronic smoking devices, vape liquids and nicotine salts. Individuals who illegally move these products across Russia’s customs border or its state border with other Eurasian Economic Union (EAEU) members could face up to five years in prison if shipment values exceed 100,000 rubles (about €1,000), provided all elements of a criminal offence are established.
Aug.20